Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery.
- Author:
Qing YU
1
;
Xiufang XIONG
1
;
Yi SUN
1
Author Information
1. Cancer Institute, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
pharmacology;
therapeutic use;
Drug Design;
Drug Discovery;
Enzyme Inhibitors;
pharmacology;
therapeutic use;
Humans;
Neoplasms;
enzymology;
Ubiquitin-Protein Ligases;
metabolism;
Ubiquitination;
drug effects
- From:
Journal of Zhejiang University. Medical sciences
2020;49(1):1-19
- CountryChina
- Language:Chinese
-
Abstract:
Cullin-RING E3 ligases (CRLs) are the major components of ubiquitin-proteasome system, responsible for ubiquitylation and subsequent degradation of thousands of cellular proteins. CRLs play vital roles in the regulation of multiple cellular processes, including cell cycle, cell apoptosis, DNA replication, signalling transduction among the others, and are frequently dysregulated in many human cancers. The discovery of specific neddylation inhibitors, represented by MLN4924, has validated CRLs as promising targets for anti-cancer therapies with a growing market. Recent studies have focused on the discovery of the CRLs inhibitors by a variety of approaches, including high through-put screen, virtual screen or structure-based drug design. The field is, however, still facing the major challenging, since CRLs are a large multi-unit protein family without typical active pockets to facilitate the drug design, and enzymatic activity is mainly dependent on undruggable protein-protein interactions and dynamic conformation changes. Up to now, most reported CRLs inhibitors are aiming at targeting the F-box family proteins (e.g., SKP2, β-TrCP and FBXW7), the substrate recognition subunit of SCF E3 ligases. Other studies reported few small molecule inhibitors targeting the UBE2M-DCN1 interaction, which specifically inhibits CRL3/CRL1 by blocking the cullin neddylation. On the other hand, several CRL activators have been reported, such as plant auxin and immunomodulatory imide drugs, thalidomide. Finally, proteolysis-targeting chimeras (PROTACs) has emerged as a new technology in the field of drug discovery, specifically targeting the undruggable protein-protein interaction. The technique connects the small molecule that selectively binds to a target protein to a CRL E3 via a chemical linker to trigger the degradation of target protein. The PROTAC has become a hotspot in the field of E3-ligase-based anti-cancer drug discovery.
